Professor Norbert Vey Takes the Helm at MATWIN, Accelerating Cancer Innovation
PARIS, FRANCE – February 13, 2026 – In a significant development for the world of oncology, Professor Norbert Vey has been appointed President of MATWIN, Unicancer announced today. This breaking news signals a recent chapter for the organization dedicated to supporting and promoting innovative cancer projects. The appointment comes as Professor Vey succeeds Professor Fabrice Barlesi, General Director of Gustave Roussy.
A Leader in Hematology and Cancer Research
Professor Vey brings a wealth of experience to his new role. Currently the Director General of the Institut Paoli-Calmettes (IPC) in Marseille, he is also a Professor of hematology at Aix-Marseille University and chairs the Cancéropôle Provence-Alpes-Côte d’Azur. His expertise lies particularly in the management of acute leukemia, a field where he has authored over 360 scientific publications and pioneered new therapies for acute leukemia and myelodysplastic syndromes. His training at the MD Anderson Cancer Center in Houston, United States, further solidifies his international standing.
MATWIN: A Hub for Oncology Innovation
MATWIN, created in 2009, operates as an open innovation platform in oncology, collaborating with approximately fifteen international laboratories. The organization plays a crucial role in fostering collaboration between researchers, industrialists and other key players in the cancer ecosystem. It’s known for its annual conference, a vital event for promoting knowledge exchange and accelerating the development of new cancer treatments.
Unicancer’s Vision for the Future
MATWIN is a 100% subsidiary of Unicancer, the hospital federation representing the 18 French cancer control centers (CLCCs). Professor Jean-Yves Blay, President of Unicancer, expressed his enthusiasm for Professor Vey’s appointment, stating that he is confident Professor Vey will “continue transformation and growth” within the organization. Unicancer’s broader strategy, “Horizon 2030,” emphasizes cooperative dynamics in oncology, and MATWIN is central to achieving these goals.
Professor Blay also extended gratitude to Professor Barlesi for his dedication and strategic contributions to MATWIN’s development. This transition underscores the commitment to sustained progress in the fight against cancer.
The appointment of Professor Vey marks a pivotal moment for MATWIN and the wider French oncology landscape. His leadership promises to further accelerate the translation of cutting-edge research into tangible benefits for patients, ensuring that the latest innovations reach those who need them most. As MATWIN continues to evolve, its dedication to open innovation and collaborative partnerships will remain at the forefront of its mission to conquer cancer.
